A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy of Placebo When Added to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Cediranib; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Aug 2011 New trial record
- 10 May 2011 This trial is recruiting in Czech Republic and discontinued in United Kingdom.